Evolus (EOLS)
(Delayed Data from NSDQ)
$16.55 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Evolus, Inc. [EOLS]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Company: Evolus, Inc.
Industry: Medical - Products
Another Beat Leads to a Guidance Boost as Profitability is Achieved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Positive Evolysse Dermal Filler Data Clear the Path for Market Entry; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Another Beautiful Quarter For Evolus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Evolus Starting To Flex Earnings Power As It Marches Towards Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Hugel Wins Approval But Impact on Neurotoxin Market Likely Small For the Foreseeable Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Evolysse Filler Line Could Be the ''Game-Changer''; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Another Strong Quarter and Guidance to Match; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Evolus Becomes a Complete Global Player in Injectable Aesthetics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for EOLS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Continues to Knock Out 11s With Record Revenues; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Evolus? Brand Evolution Should Not Be Overlooked; Raise PT to $27; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Evolus Presents Evolysse, New Potential Entrant to the Dermal Filler Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Shows Healthy Growth and Room to Keep Going; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau?s ?Extra-Strength? Formulation Offers Six-Month Long Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
The Present and Future Look Bright for Evolus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Seasonality, Macro Impact 3Q, But Share Gains Bode Well for Future; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Another Strong Quarter But Macro Backdrop Fosters Some Uncertainty
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D